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Summary
Background Cervical cancer screening might contribute to the prevention of anal cancer in women. We aimed to 
investigate if routine cervical cancer screening results—namely high-risk human papillomavirus (HPV) infection and 
cytohistopathology—predict anal HPV16 infection, anal high-grade squamous intraepithelial lesions (HSIL) and, 
hence, anal cancer.
Methods We did a systematic review of MEDLINE, Embase, and the Cochrane library for studies of cervical 
determinants of anal HPV and HSIL published up to Aug 31, 2018. We centrally reanalysed individual-level data from 
13 427 women with paired cervical and anal samples from 36 studies. We compared anal high-risk HPV prevalence by 
HIV status, cervical high-risk HPV, cervical cytohistopathology, age, and their combinations, using prevalence ratios 
(PR) and 95% CIs. Among 3255 women with anal cytohistopathology results, PRs were similarly calculated for all 
anal HSIL and HPV16-positive anal HSIL.
Findings Cervical and anal HPV infections were highly correlated. In HIV-negative women, anal HPV16 prevalence 
was 41% (447/1097) in cervical HPV16-positive versus 2% (214/8663) in cervical HPV16-negative women (PR 16·5, 
95% CI 14·2–19·2, p<0·0001); these values were 46% (125/273) versus 11% (272/2588) in HIV-positive women 
(4·4, 3·7–5·3, p<0·0001). Anal HPV16 was also associated with cervical cytohistopathology, with a prevalence of 
44% [101/228] for cervical cancer in HIV-negative women (PR vs normal cytology 14·1, 11·1–17·9, p<0·0001). Anal 
HSIL was associated with cervical high-risk HPV, both in HIV-negative women (from 2% [11/527] in cervical high-
risk HPV-negative women up to 24% [33/138] in cervical HPV16-positive women; PR 12·9, 95% CI 6·7–24·8, 
p<0·0001) and HIV-positive women (from 8% [84/1094] to 17% [31/186]; 2·3, 1·6–3·4, p<0·0001). Anal HSIL was 
also associated with cervical cytohistopathology, both in HIV-negative women (from 1% [5/498] in normal cytology up 
to 22% [59/273] in cervical HSIL; PR 23·1, 9·4–57·0, p<0·0001) and HIV-positive women (from 7% [105/1421] to 
25% [25/101]; 3·6, 2·5–5·3, p<0·0001). Prevalence of HPV16-positive anal HSIL was 23–25% in cervical 
HPV16-positive women older than 45 years (5/20 in HIV-negative women, 12/52 in HIV-positive women).
Interpretation HPV-based cervical cancer screening programmes might help to stratify anal cancer risk, irrespective 
of HIV status. For targeted secondary anal cancer prevention in high-risk groups, HIV-negative women with 
cervical HPV16, especially those older than 45 years, have a similar anal cancer risk profile to that of HIV-positive 
women.
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Introduction
Compared with knowledge of how cervical high-risk 
human papillomavirus (HPV) infection and cervical 
cytohistopathological results are related to cervical 
cancer, less is known about how cervical screening 
results might predict anal cancer. A better understanding 
would help to prioritise women at greatest risk of 
anal cancer for secondary prevention measures in new 
HPV-based cervical cancer screening programmes.
Annually, about 18 000 women are diagnosed with anal 
cancer worldwide1 and, although rare at a population 
level, anal cancer is more frequent in women than in 
men.2 Furthermore, anal cancer incidence rates are 
increasing,2 probably owing to changes in sexual risk 
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factors for HPV transmission.3 Persistent anal HPV 
infection is the major cause of anal cancer,4 for which the 
most severe precursor is anal high-grade squamous 
intraepithelial lesion (HSIL).5 In particular, HPV16 is 
detectable in over 90% of HPV-related anal cancers and 
80% of HPV-related anal HSIL5, a substantially higher 
attributable fraction than in the cervix. Anal cancer risk is 
also elevated in women infected with HIV,6–8 although 
HIV does not account for a substantial proportion of anal 
cancer in women at a population level.9,10 Women with a 
history of cervical cancer9,11,12 and cervical intraepithelial 
neoplasia grade 3 (CIN3)13–15 are also at increased risk for 
anal cancer.
To assess the association between cervical screening 
findings and surrogates of anal cancer risk, we did a col-
laborative pooled analysis of high-risk HPV and related 
lesions in paired anal and cervical samples. We hypo-
thesised that it would be possible, based on HIV status 
and cervical screening results, to robustly identify sub-
groups of women with high prevalence of anal HPV16, 
anal HSIL, or HPV16-positive anal HSIL for the purpose 
of targeting anal cancer screening and early diagnosis.
Methods
Data collection
We previously did a systematic literature review for a meta-
analysis of anal HPV prevalence according to anal 
cytohistopathology, sex, and HIV status. We searched 
MEDLINE, Embase, and the Cochrane Library for studies 
published between Jan 1, 1986, and July 31, 2017, using the 
terms (“papillomaviridae” OR “papillomavirus” OR 
“HPV”) AND (“anal canal” OR “anus” OR “anal”).5 The 
same search strategy was extended to Aug 31, 2018 and 
identified 49 studies eligible for a pooled analysis of cervical 
determinants of anal HPV and HSIL (appendix p 2). 
Minimum eligibility criteria were paired anal and cervical 
samples (swabs or biopsies, or both) taken at the same 
study visit; in anal samples, type-specific HPV DNA 
detected by a PCR-based assay; and, in cervical samples, 
type-specific HPV DNA detected by a PCR-based assay, 
cytohistopathology results, or both. Authors of eligible 
studies were invited to share individual-level data on 
age, anal and cervical HPV genotyping, cervical cyto-
histopathology, and HIV status (including unknown HIV 
status), of which 36 accepted (appendix p 2). Anal 
cytohistopathology results from the same study visit were 
also extracted, if available, as were current and nadir CD4 
cell count and HIV-1 viral load for HIV-positive women.
Statistical analysis
Type-specific HPV prevalence in the anus and cervix is 
reported for 13 high-risk HPV types judged to be 
carcinogenic or probably carcinogenic (HPV16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68),4 and is estimated 
only in studies that tested for the given high-risk HPV 
type, thus denominators vary by type, as in previous 
similar meta-analyses.5,16 Anal HPV16 prevalence was 
available in all studies.
Anal and cervical cytohistopathological diagnoses were 
classified into four categories, as done previously:5,16 normal, 
including normal cytology only; low grade, including 
atypical squamous cells of undetermined significance, low-
grade squamous intraepithelial lesion, and intraepithelial 
neoplasia grade 1; high grade, including HSIL, atypical 
squamous cells for which HSIL cannot be excluded, 
intraepithelial neoplasia grade 2–3; and invasive cancer. We 
Research in context
Evidence before this study
We searched MEDLINE, Embase, and the Cochrane Library for 
studies published between database inception and 
Aug 31, 2018, using the search terms (“papillomaviridae” OR 
“papillomavirus” OR “HPV”) AND (“anal” OR “anus” OR “anal 
canal”), without language restrictions. A large systematic 
review and meta-analysis has shown the predominant role of 
HPV16 in the pathogenesis of anal high grade squamous 
intraepithelial lesion (HSIL) and cancer, both in men and 
women, and according to HIV status. Various studies, 
predominantly from high-income settings, have also shown 
that anal cancer incidence is higher in women than in men, 
is increasing over time and, among women, is particularly 
elevated in those with cervical precancer or cancer, or living 
with HIV. However, there has been no systematic appraisal of 
how routinely available information from cervical cancer 
screening—ie, cervical HPV infection and 
cytohistopathology—is predictive of risk of 
anal cancer or its surrogates.
Added value of this study
This collaborative pooled analysis is the first systematic effort to 
address how routinely available information from modern 
cervical cancer screening programmes—cervical HPV and 
cytohisto pathology results—can predict anal HPV16, anal HSIL, 
or HPV16-positive anal HSIL, as best surrogates of anal cancer 
risk in women. We showed that cervical HPV infection, cervical 
cyto histopathological diagnosis, HIV status, and their 
combinations, are all associated with anal HPV16, 
anal HSIL, or HPV16-positive anal HSIL. The strongest 
determinants of these outcomes were the presence of cervical 
HPV16 infection or a diagnosis of cervical cancer, irrespective of 
HIV status. The degree of HIV-related immunodeficiency 
was also weakly associated.
Implications of all the available evidence
Women with cervical HPV16 infection or cervical cancer are at 
highest risk of anal HPV16, anal HSIL, or HPV16-positive anal 
HSIL. HPV-based cervical screening programmes might help to 
stratify anal cancer risk in women, irrespective of their HIV status.
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calculated prevalence ratios (PRs) from generalised linear 
models, with adjustment for age (<30 years, 30–44 years, 
and >45 years). Age-adjusted PRs and corresponding 
95% CIs were used to compare prevalence of type-specific 
anal HPV (most notably HPV16), anal high-grade lesions 
(ie, HSIL),17 and HPV16-positive anal HSIL, according to 
cervical high-risk HPV status, cervical cytohistopathology, 
age (<30 years, 30–44 years, and >45 years), and HIV status 
(negative or unknown vs positive). Among HIV-positive 
women, PRs were also calculated according to current 
CD4 cell count (<350 cells per μL, 350–499 cells per μL, or 
>500 cells per μL; defined as rough tertiles of available 
data), nadir CD4 count (<200 cells per μL or >200 cells per 
μL), and HIV viral load (<200 copies per mL or >200 copies 
per mL). All statistical analyses were two-sided and done in 
Stata (version 14).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all data in the study and had final responsibility for the 
decision to submit for publication.
Results
We included 36 studies contributing individual-level 
data on 13 427 women, representing 87% of 
15 521 eligible women identified by our literature review 
(appendix p 2). 3352 women were HIV-positive, 
3607 were HIV-negative, and 6468 had an unknown 
HIV status. Study characteristics are shown in 
table 1.18–53 Most women with an unknown HIV status 
(5972 [92%] of 6468) came from three population-based 
studies in China, the USA, and Costa Rica (table 1). 
Furthermore, a preliminary analysis of women with 
normal cytology showed equivalent cervical and anal 
HPV prevalence in HIV-negative women and women 
with unknown HIV status (appendix p 3). Hence, 
participants with unknown HIV status are hereafter 
assumed to be HIV-negative.
Country HIV status n HPV genotyping Cytohistopathology HIV-positive women
Anal Cervical Anal Cervical Current 
CD4 cell 
count
Nadir 
CD4 cell 
count
HIV-1 
viral load
Sohn et al (2018)18 Thailand and 
Vietnam
Negative 98 Yes Yes No Yes ·· ·· ··
Sohn et al (2018)18 Thailand and 
Vietnam
Positive 93 Yes Yes No Yes Yes No Yes
Cranston et al (2018)19 USA Positive 103 Yes Yes Yes Yes Yes Yes Yes
de Pokomandy et al (2017)20 Canada Positive 151 Yes Yes Yes Yes Yes Yes Yes
Wei et al (2018)21 China Unknown 2283 Yes Yes No No ·· ·· ··
Volpini et al (2017)22 Brazil Positive 126 Yes Yes No Yes Yes No Yes
Marra et al (2018)23 Netherlands Unknown 1 Yes No No No ·· ·· ··
Marra et al (2018)23 Netherlands Negative 285 Yes Yes No No ·· ·· ··
Marra et al (2018)23 Netherlands Positive 2 Yes Yes No No No No No
Hidalgo-Tenorio et al (2018)24 Spain Positive 101 Yes Yes Yes Yes Yes Yes Yes
Gonzalez-Losa et al (2018)25 Mexico Unknown 305 Yes Yes No Yes ·· ·· ··
Goeieman et al (2017)26 South Africa Positive 200 Yes No Yes Yes Yes Yes Yes
Dube Mandishora et al (2017)27 Zimbabwe Negative 74 Yes Yes No Yes ·· ·· ··
Dube Mandishora et al (2017)27 Zimbabwe Positive 70 Yes Yes No Yes No No No
Simpson et al (2016)28 Australia Negative 163 Yes Yes Yes Yes ·· ·· ··
Ortiz et al (2016)29 Puerto Rico Negative 536 Yes Yes No No ·· ·· ··
Menezes et al (2016)30 India Positive 46 Yes Yes No No Yes Yes Yes
Heard et al (2016)31 France Positive 311 Yes Yes Yes Yes Yes Yes Yes
Veo et al (2015)32 Brazil Negative 220 Yes Yes No Yes ·· ·· ··
Tso et al (2015)33 Brazil Negative 56 Yes Yes Yes Yes ·· ·· ··
Tso et al (2015)33 Brazil Positive 42 Yes Yes Yes Yes Yes No No
Slama et al (2015)34 Czech Republic Negative 1085 Yes Yes No Yes ·· ·· ··
Robison et al (2015)35 USA Negative 174 Yes Yes Yes Yes ·· ·· ··
Ramautarsing et al (2015)36 Thailand Positive 101 Yes Yes Yes Yes Yes No Yes
Cambou et al (2015)37 Brazil Positive 478 Yes Yes Yes Yes Yes Yes Yes
Kojic et al (2014)38 USA, Brazil, 
South Africa
Positive 300 Yes Yes No No Yes Yes Yes
Godbole et al (2014)39 India Positive 98 Yes Yes No Yes Yes No No
(Table 1 continues on next page)
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Cervical high-risk HPV positivity was associated with 
anal high-risk HPV prevalence (table 2). In HIV-negative 
women, anal high-risk HPV prevalence was 43% 
(1160/2693) in cervical high-risk HPV-positive women 
versus 9% (563/6543) in cervical high-risk HPV-negative 
women (PR 4·9, 95% CI 4·4–5·3, p<0·0001). In 
HIV-positive women, these proportions were 62% 
(678/1091) for HPV-positive women and 33% (579/1770) 
for HPV-negative women (1·9, 1·7–2·1, p<0·0001). 
Associations for individual high-risk HPV types were 
much stronger than for high-risk HPV overall (table 2). 
For example, for HIV-negative women, anal HPV16 
prevalence was 41% (447/1097) in cervical HPV16-positive 
versus 2% (214/8663) in cervical HPV16-negative women 
(16·5, 14·2–19·2, p<0·0001; table 2). Equivalent pro-
portions were 46% (125/273) and 11% (272/2588) in HIV-
positive women (4·4, 3·7–5·3, p<0·0001).
For each high-risk HPV type, the association between 
cervical and anal positivity was weaker among HIV-
positive than HIV-negative women (table 2). In cervical 
HPV16-negative women, anal HPV16 prevalence was 
11% in HIV-positive women versus 2% in HIV-negative 
women (PR 3·9, 95% CI 3·3–4·7, p<0·0001); whereas, 
in HPV16-positive women, anal HPV16 prevalence was 
46% in HIV-positive women versus 41% in HIV-negative 
women (1·1, 1·0–1·3, p=0·1501). Anal HPV16 prevalence 
was higher in cervical high-risk HPV-positive women 
than in cervical high-risk HPV-negative, regardless of 
HIV status (PR 9·2, 95% CI 7·5–11·2, p<0·0001 for 
HIV-negative women vs 2·4, 2·0–2·9, p<0·0001 for HIV-
positive women; figure 1). Anal HPV16 prevalence was 
highest among cervical HPV16-positive women (table 2), 
but was also significantly higher in women infected with 
cervical non-HPV16 high-risk HPV than in women 
without high-risk HPV (2·1, 1·5–2·8, p<0·0001 for HIV-
negative; 1·5, 1·2–1·9, p=0·0003 for HIV-positive 
women).
Cervical cytohistopathology was strongly associated with 
anal HPV16, particularly in HIV-negative women, among 
whom it increased from 4% (155/4358) in women with 
normal cytology to 22% (251/1131) in those with HSIL 
(PR 6·5, 95% CI 5·4–7·9, p<0·0001) and to 44% (101/228) 
in those with cervical cancer (14·1, 11·1–17·9, p<0·0001; 
figure 1A). Associations were also significant, albeit lower, 
in HIV-positive women (13% [230/1821] for normal 
cytology up to 23% [29/127] for HSIL; 1·9, 1·3–2·6, 
p=0·0004). Age was not a strong determinant of anal 
HPV16 prevalence, regardless of HIV status. Cervical 
cancer cases in HIV-positive women were too few (n=3) to 
be analysed separately.
Country HIV status n HPV genotyping Cytohistopathology HIV-positive women
Anal Cervical Anal Cervical Current 
CD4 cell 
count
Nadir 
CD4 cell 
count
HIV-1 
viral load
(Continued from previous page)
Vriend et al (2013)40 Netherlands Unknown 2 Yes Yes No No ·· ·· ··
Vriend et al (2013)40 Netherlands Negative 142 Yes Yes No No ·· ·· ··
Vriend et al (2013)40 Netherlands Positive 1 Yes Yes No No No No No
Ortiz et al (2013)41 Puerto Rico Negative 99 Yes Yes No Yes ·· ·· ··
Hessol et al (2013)42 USA Negative 176 Yes Yes Yes Yes ·· ·· ··
Hessol et al (2013)42 USA Positive 457 Yes Yes Yes Yes Yes No Yes
Hernandez et al (2013)43 USA Unknown 188 Yes Yes No Yes ·· ·· ··
Pierangeli et al (2012)44 Italy Negative 108 Yes Yes Yes Yes ·· ·· ··
Pierangeli et al (2012)44 Italy Positive 15 Yes Yes Yes Yes No No No
D’Hauwers et al (2012)45 Belgium Negative 93 Yes Yes Yes Yes ·· ·· ··
Castro et al (2012)46 Costa Rica Unknown 2107 Yes Yes No Yes ·· ·· ··
Kojic et al (2011)47 USA Positive 152 Yes Yes Yes Yes Yes Yes Yes
Heraclio et al (2011)48 Brazil Negative 37 Yes Yes Yes Yes ·· ·· ··
Park et al (2009)49 USA Negative 101 Yes No Yes Yes ·· ·· ··
Goncalves et al (2008)50 Brazil Positive 102 Yes Yes No No Yes No No
Hernandez et al (2005)51 USA Unknown 1582 Yes Yes No Yes ·· ·· ··
Moscicki et al (2003)52 USA Negative 128 Yes Yes Yes Yes ·· ·· ··
Moscicki et al (2003)52 USA Positive 238 Yes Yes Yes Yes Yes No Yes
Palefsky et al (2001)53 USA Negative 32 Yes Yes Yes Yes ·· ·· ··
Palefsky et al (2001)53 USA Positive 165 Yes Yes Yes Yes Yes No Yes
Overall ·· ·· 13 427 ·· ·· ·· ·· ·· ·· ··
HPV=human papillomavirus.
Table 1: Principal characteristics of 36 included studies
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Among cervical HPV16-positive women, anal HPV16 
prevalence reached 66% [90/136] in cervical cancer 
(figure 1B). However, neither cytohistopathology, nor 
age, offered much discrimination of anal HPV16 
prevalence, neither for HIV-negative nor HIV-positive 
women. Anal HPV16 prevalence according to other 
strata of cervical high-risk HPV status (cervical high-risk 
HPV-negative, cervical high-risk HPV-positive, and 
cervical non-HPV16 high-risk HPV-positive only) is 
shown in the appendix (p 4).
HIV status was a determinant of anal HPV16 prevalence 
within almost all strata of cervical cytohistopathology and 
age (figure 1A), but not in any stratum of cervical HPV16-
positive women (figure 1B).
A subset of studies had data on anal cytohistopathology 
(1003 HIV-negative women from ten studies and 
2252 HIV-positive women from 13 studies, table 1). Anal 
HSIL was associated with cervical high-risk HPV, both 
in HIV-negative women (from 2% [11/527] in cervical 
high-risk HPV-negative women up to 24% [33/138] in 
cervical HPV16-positive women; PR 12·9, 95% CI 
6·7–24·8, p<0·0001) and HIV-positive women (from 8% 
[84/1094] to 17% [31/186]; 2·3, 1·6–3·4, p<0·0001). 
Cervical high-risk HPV-positive women had higher anal 
HSIL prevalence than did cervical high-risk HPV-
negative women, regardless of HIV status (PR 10·4, 
95% CI 5·5–19·5, p<0·0001 for HIV-negative women; 
1·7, 1·3–2·2, p=0·0001 for HIV-positive women; 
figure 2A). For cervical HPV16-positive women, PRs 
versus cervical high-risk HPV-negative women reached 
12·9 (95% CI 6·7–24·8, p<0·0001) and 2·3 (1·6–3·4, 
p<0·0001), for HIV-positive and HIV-negative women, 
respectively. Anal HSIL was also more common among 
women with cervical HPV16 than among women with 
cervical non-16 high-risk HPV, both in HIV-negative 
women (1·5, 1·0–2·5, p=0·0666) and HIV-positive 
women (1·6, 1·1–2·3, p=0·0227). Anal HSIL was 
associated with cervical cytohistopathology, particularly 
with cervical HSIL (PR vs normal cytology 23·1, 9·4–57·0, 
p<0·0001 in HIV-negative women, 3·6, 2·5–5·3, 
p<0·0001 in HIV-positive women) and cervical cancer 
(15·0, 4·3–52·3, p<0·0001 in HIV-negative women; 
figure 2A). Anal HSIL prevalence increased with age, 
but was significantly different only in HIV-positive 
women (2·5, 1·6–4·1, p=0·0001; figure 2A).
Among cervical HPV16-positive women, anal HSIL 
prevalence increased with advancing age (figure 2B). In 
HIV-negative women, HSIL prevalence was 38% (8/21) 
in those older than 45 years versus 17% (9/52) in those 
younger than 30 years (PR 2·2, 95% CI 1·0–4·9, 
p=0·0552); these values were 26% (14/53) versus 
5% (3/58) in HIV-positive women (5·1, 1·6–16·8, 
p=0·0072; figure 2B). Anal HSIL prevalence is shown 
for other strata of cervical high-risk HPV status in the 
appendix (p 5).
HIV status was a significant determinant of anal HSIL 
for women in lower risk strata—for example, cervical 
high-risk HPV-negative women (PR 3·5, 95% CI 
1·9–6·5, p=0·0001; figure 2A) and women with normal 
cervical cytology (PR 6·9, 2·8–16·9, p<0·0001; 
figure 2A)—but was not a significant determinant 
HIV-negative women HIV-positive women PR* (95% CI) 
(HIV-positive vs 
HIV-negative)
n/N (%) PR* (95% CI) n/N (%) PR* (95% CI)
HPV16
Negative 214/8663 (2%) 1 (ref) 272/2588 (11%) 1 (ref) 3·9 (3·3–4·7)
Positive 447/1097 (41%) 16·5 (14·2–19·2) 125/273 (46%) 4·4 (3·7–5·3) 1·1 (1·0–1·3)
HPV18
Negative 115/9448 (1%) 1 (ref) 153/2716 (6%) 1 (ref) 4·4 (3·4–5·6)
Positive 93/312 (30%) 24·1 (18·8–30·9) 58/145 (40%) 7·1 (5·5–9·1) 1·4 (1·1–1·9)
HPV31
Negative 95/8850 (1%) 1 (ref) 110/2542 (4%) 1 (ref) 3·9 (2·9–5·2)
Positive 79/280 (28%) 24·2 (18·3–31·9) 43/121 (36%) 7·7 (5·7–10·4) 1·4 (1·0–2·0)
HPV33
Negative 47/8968 (1%) 1 (ref) 78/2571 (3%) 1 (ref) 5·0 (3·4–7·3)
Positive 37/162 (23%) 43·5 (29·1–65·1) 38/92 (41%) 13·8 (10·0–19·0) 1·9 (1·3–2·7)
HPV35
Negative 51/9000 (1%) 1 (ref) 88/2580 (3%) 1 (ref) 6·1 (4·3–8·8)
Positive 29/130 (22%) 36·4 (23·9–55·6) 22/83 (27%) 7·9 (5·2–11·9) 1·9 (1·1–3·1)
HPV39
Negative 105/9006 (1%) 1 (ref) 92/2791 (3%) 1 (ref) 2·9 (2·2–3·8)
Positive 66/230 (29%) 22·4 (16·8–29·8) 24/70 (34%) 10·6 (7·3–15·4) 1·2 (0·8–1·8)
HPV45
Negative 71/9369 (1%) 1 (ref) 128/2759 (5%) 1 (ref) 5·8 (4·3–7·8)
Positive 45/172 (26%) 33·9 (24·1–47·7) 39/102 (38%) 8·0 (5·9–10·8) 1·5 (1·0–2·1)
HPV51
Negative 180/8899 (2%) 1 (ref) 157/2728 (6%) 1 (ref) 2·9 (2·3–3·6)
Positive 117/337 (35%) 15·1 (12·2–18·6) 48/133 (36%) 5·8 (4·4–7·7) 1·1 (0·8–1·5)
HPV52
Negative 132/8756 (2%) 1 (ref) 138/2686 (5%) 1 (ref) 3·5 (2·7–4·4)
Positive 147/480 (31%) 18·8 (15·2–23·4) 54/175 (31%) 6·4 (4·9–8·4) 1·0 (0·8–1·3)
HPV56
Negative 74/9051 (1%) 1 (ref) 99/2736 (4%) 1 (ref) 4·3 (3·2–5·9)
Positive 62/185 (34%) 35·9 (26·2–49·1) 36/125 (29%) 7·8 (5·6–10·9) 0·9 (0·6–1·4)
HPV58
Negative 118/9269 (1%) 1 (ref) 178/2622 (7%) 1 (ref) 4·8 (3·8–6·1)
Positive 74/272 (27%) 21·3 (16·3–27·7) 75/239 (31%) 4·6 (3·6–5·8) 1·2 (0·9–1·6)
HPV59
Negative 52/8974 (1%) 1 (ref) 87/2559 (3%) 1 (ref) 5·7 (4·0–8·2)
Positive 48/156 (31%) 49·2 (34·1–70·9) 36/104 (35%) 10·2 (7·3–14·2) 1·3 (0·9–2·0)
HPV68
Negative 52/6932 (1%) 1 (ref) 127/2582 (5%) 1 (ref) 6·1 (4·4–8·5)
Positive 30/91 (33%) 42·4 (28·2–63·7) 36/81 (44%) 8·9 (6·6–12·0) 1·5 (1·0–2·2)
HR-HPV (any)
Negative 563/6543 (9%) 1 (ref) 579/1770 (33%) 1 (ref) 3·8 (3·4–4·2)
Positive 1160/2693 (43%) 4·9 (4·4–5·3) 678/1091 (62%) 1·9 (1·7–2·1) 1·4 (1·4–1·5)
HR-HPV=high-risk human papillomavirus. *Adjusted by age groups.
Table 2: Anal high-risk HPV prevalence and corresponding prevalence ratios, according to the absence or 
presence of the same type in the cervix, by HIV status
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in any stratum of cervical HPV16-positive women 
(figure 2B).
Prevalence of HPV16-positive anal HSIL was 
substantially higher in cervical high-risk HPV-positive 
women than in high-risk HPV-negative women (PR 14·8, 
95% CI 3·3–66·3, p=0·0004 for HIV-negative and 
3·0, 1·8–4·8, p<0·0001 for HIV-positive women; 
figure 3A), largely due to the strong association with 
cervical HPV16-positivity (24·9, 5·5–112·7, p<0·0001 for 
HIV-negative women and 6·2, 3·6–10·6 p<0·0001 for 
HIV-positive women; figure 3A). There were also 
significant associations with cervical cytohistopathology, 
most clearly with cervical HSIL versus normal cytology 
(PR not defined, 95% CI 2·6–∞ in HIV-negative women 
and PR 4·3, 2·4–7·8, p<0·0001 in HIV-positive women), 
but not with age (figure 3A).
In cervical HPV16-positive women, there was a strong 
association between HPV16-positive anal HSIL and age 
(figure 3B). In HIV-negative women, HPV16-positive 
anal HSIL prevalence was 25% (5/20) in women older 
than 45 years versus 4% (2/46) in women younger 
than 30 years (PR 5·8, 1·2–27·2, p=0·0273); in HIV-
positive women, these values were 23% (12/52) versus 
2% (1/55; 12·7, 1·7–94·2, p=0·0130). HPV16-positive 
anal HSIL prevalence is shown for other strata of cervical 
high-risk HPV status in the appendix (p 6).
Figure 1: Prevalence of anal HPV16 infection, by cervical high-risk HPV infection, cervical cytohistopathology, age, and HIV status
Data are for all women (A) and cervical HPV16-positive women only (B). HPV16=human papillomavirus 16. PR=prevalence ratio. *Adjusted by age. †Coinfections of 
non-HPV16 high-risk HPV types and HPV16 are not included. ‡The denominator for HPV16 is different from that in table 2 because one study was excluded for 
reporting HPV16 prevalence, but not high-risk HPV prevalence.
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HIV status was a significant determinant of HPV16-
positive anal HSIL in cervical high-risk HPV-negative 
women (PR 5·2, 95% CI 1·2–22·1, p=0·0242; figure 3A), 
women with normal cervical cytology (PR not defined, 
2·1–∞, p<0·0001), and with cervical HSIL (2·7, 1·2–5·9, 
p=0·0142), but not in any stratum of cervical HPV16-
positive women (figure 3B).
In HIV-positive women (appendix p 7), current CD4 cell 
count was significantly, albeit weakly, associated with 
anal HPV16 (for <350 cells per μL vs >500 cells per μL; 
PR 1·6, 95% CI 1·3–1·9, p<0·0001), anal HSIL 
(1·7, 1·3–2·2, p=0·0003), and HPV16-positive anal HSIL 
(1·6, 1·0–2·6, p=0·0365). Similar findings were seen for 
nadir CD4 cell count (appendix p 7). HIV viral load was 
positively associated with anal HPV16, but not with anal 
HSIL or HPV16-positive anal HSIL (appendix p 7).
Among HIV-positive women with cervical HPV16 
infection (appendix p 7), anal HPV16 prevalence was 
highest in cervical HPV16-positive women with a current 
CD4 cell count of less than 350 cells per μL. No 
associations were seen for cervical HPV16-positive 
women in terms of HIV-related immunosuppression and 
anal HSIL nor HPV16-positive anal HSIL (appendix p 7).
Discussion
This collaborative pooled analysis is, to our knowledge, the 
first systematic effort to address how routine information 
from modern cervical cancer screening programmes 
Figure 2: Prevalence of anal HSIL, by cervical high-risk HPV infection, cervical cytohistopathology, age, and HIV status
Data are for all women (A) and cervical HPV16-positive women only (B). HSIL=high-grade squamous intraepithelial lesions. HPV16=human papillomavirus 16. 
PR=prevalence ratio. *Adjusted by age. †Coinfections of non-HPV16 HR HPV types and HPV16 are not included.
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might help to determine anal cancer risk. The findings 
show that cervical high-risk HPV infection, cervical 
cytohistopathological diagnosis, HIV status, and their 
combinations are all important determinants of a woman’s 
anal cancer risk profile. The strongest determinants are a 
diagnosis of cervical cancer and cervical HPV16 positivity. 
HIV infection and severity of immunodeficiency are also 
strong determinants, but they offer little additional risk 
discrimination over status of cervical HPV genotype and 
cytohistopathology. Findings were broadly similar whether 
using anal HPV16 infection or anal HSIL as an outcome, 
and were consistent when restricted to a combined 
outcome of HPV16-positive anal HSIL, which highlighted 
age as a strong determinant of risk in cervical HPV16-
positive women.
A strong association between the presence of high-risk 
HPV in cervical and anal specimens was confirmed.46,51 
However, the pooled analysis showed an even stronger 
association at the HPV type-specific level, suggesting 
shared exposure routes, with the cervix serving as a 
reservoir for HPV cross-infection of the anus or vice 
versa.54 Given that studies in women have reported 
associations between anal sexual intercourse and anal 
HPV to be either non-significant,47 or less important than 
number of sexual partners per se,46,51 it is likely that HPV 
exposure is predominantly from cervix to anus. This 
Figure 3: Prevalence of HPV16-positive anal HSIL, by cervical high-risk HPV infection, cervical cytohistopathology, age, and HIV status
Data are for all women (A) and cervical HPV16-positive women only (B). HPV16=human papillomavirus 16. HSIL=high-grade squamous intraepithelial lesions. 
PR=prevalence ratio. ND=not defined *Adjusted by age. †Coinfections of non-HPV16 HR HPV types and HPV16 are not included.
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exposure could be assisted by a sexual partner or, given the 
close anatomical proximity, non-sexual autoinoculation. 
These findings highlight notable differences from anal 
HPV transmission in men.55
Given the unique anal carcinogenicity of HPV16,5 our 
primary objective was to measure female determinants of 
anal HPV16 prevalence as a surrogate of anal cancer risk. 
The prevalence of anal HPV16 is about 30% in HIV-positive 
men who have sex with men (MSM),55 a population widely 
considered to be at a clinically relevant elevated risk of 
anal cancer, and the focus of numerous anal cancer 
prevention recommendations.56–58 Using this benchmark, 
female subpopulations with clinically relevant elevated 
anal HPV16 prevalence included women with cervical 
cancer (44%), corroborating the excess anal cancer risk 
found in cancer registry-based studies,11–13 followed by 
those with cervical HPV16 infection (39% in HIV-negative 
women, 46% in HIV-positive women), for which no 
studies of anal cancer outcomes exist.
In the absence of cervical genotyping for HPV16 or a 
history of cervical cancer, some discrimination of anal 
HPV16 prevalence can also be offered by cervical high-risk 
HPV, cervical cytopathology, and HIV status. For example, 
anal HPV16 prevalence is relatively high in HIV-positive 
women with cervical high-risk HPV infection (22%) or 
cervical HSIL (23%). In general, HIV-positive women had 
higher anal HPV16 prevalence than did HIV-negative 
women, supporting their known excess risk of anal 
cancer.6–8 Severity of immunosuppression, although a risk 
factor for anal cancer,8,59 was a relatively weak determinant 
of anal HPV16 prevalence (and anal HSIL) in HIV-positive 
women, which is consistent with findings in HIV-positive 
MSM.60,61 Given that the non-HPV16 high-risk HPV 
fraction of anal cancer is somewhat larger in HIV-positive 
than in HIV-negative women,5 anal HPV16 prevalence is 
arguably a less-specific surrogate of anal cancer risk in 
HIV-positive women. However, no other non-HPV16 
high-risk HPV type clearly stands out as being associated 
with an increased risk of anal cancer;5 not even HPV18, 
which does for cervical cancer. Therefore, we postulate 
that anal HPV16 still remains the most-specific virological 
surrogate of anal cancer risk, even in HIV-positive women.
As a complement to anal HPV16 as a surrogate for anal 
cancer risk, we also evaluated anal HSIL. Whereas anal 
HPV16 prevalence was standardly reported and measured 
by PCR-based assay in all studies, anal cytohistopathology 
was available only for about 24% of the study population. 
Furthermore, anal HSIL represents lesions reported 
according to cytology or histology (or both), the results of 
which were inextricably entwined (especially given the 
move towards harmonisation of cytology or histology 
nomenclature),17 and might also be influenced by differing 
expertise in high-resolution anoscopy to detect biopsy-
directed histological HSIL.62 Despite these caveats, 
patterns of anal HSIL were broadly similar to those found 
for anal HPV16, with positivity for cervical HPV16 
infection (24% prevalence of anal HSIL in HIV-negative 
women) or history of cervical cancer (17% prevalence of 
anal HSIL) being strong determinants of anal HSIL risk. 
These values compare to 24% prevalence of histological 
HSIL estimated in a large meta-analysis of HIV-positive 
MSM.63
22 (36%) of the 61 HIV-negative women with anal 
HSIL and 11 (5%) of the 217 HIV-positive women with 
anal HSIL were anal HPV-negative. HPV16 accounted 
for 41% (for HIV-negative women) and 42% (for HIV-
positive women) of HPV-positive anal HSIL, which 
compares to 56% (for HIV-negative women) and 36% (for 
HIV-positive women), estimated in a wider meta-analysis 
of anal HSIL.5 However, the meta-analysis showed 
further enrichment in HPV16 from anal HSIL to anal 
cancer,5 irrespective of HIV status, suggesting that 
HPV16-positive anal HSIL is the most specific anal 
cancer surrogate. Although this outcome suffers from 
the same limitations of ascertainment as anal HSIL does, 
HPV16-positive anal HSIL showed strongest risk 
discrimination (ie, highest PRs) by cervical determinants, 
most notably by cervical HPV16 infection, cervical HSIL, 
and age group. Older age offered significant additional 
discrimination of HPV16-positive anal HSIL risk in 
cervical HPV16-positive women.
With respect to population representativeness, we did 
not present outcomes for HIV-negative women overall, 
given that many studies biased recruitment towards 
HIV-negative women with cervical lesions. For example, 
whereas anal HPV16 prevalence in HIV-negative women 
was 7% overall, it was only 3% in four large population-
based studies totalling 6508 women.21,29,46,51 Strata by 
cervical HPV and cytohistopathology, however, are 
expected to be representative of these subpopulations of 
HIV-negative women. HIV-positive women are also 
likely to be representative, because studies tended to 
recruit all patients in HIV clinics in a given time frame, 
without other selection criteria.
Our study has some limitations. First, the small 
numbers in certain important strata, most notably 
cervical HPV16-positive women with respect to the 
outcome of HPV16-positive anal HSIL. Second, the 
included studies lacked data on anal outcomes related 
to three areas: in HIV-positive women with cervical 
cancer, presumably due to their relative rarity at a 
population level (although we assume that they would 
show an anal cancer risk profile at least as bad as HIV-
negative women with cervical cancer); according to the 
use of combined antiretroviral therapy (we addressed 
the issue of immune reconstitution through CD4 cell 
counts and HIV viral load); and by HPV vaccination 
status, although study years, country, and the age group 
of women suggest that most women were ineligible for 
HPV vaccination.
The rarity of anal cancer at a population level, combined 
with a scarcity of medical expertise and capacity—whether 
in digital anal rectal examination for early cancer diagnosis, 
or anal cytology in combination with high-resolution 
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anoscopy for the detection and treatment of dysplastic anal 
lesions—means that any secondary anal cancer prevention 
programme needs to target the groups at highest risk. 
Although the effectiveness of such programmes is still to 
be established,64 when such activities do exist, they should 
at least prioritise individuals according to an approach of 
equal management for equal risk. To date, secondary 
prevention in women has focused on HIV-positive 
populations and certain guidelines for HIV management 
make specific recommendations.56–58 For example, the 
European AIDS Clinical Society advises digital rectal 
examination (with or without anal cytology) every 1–3 years 
for women with cervical dysplasia;56 similarly, France 
recommends digital rectal examination and anoscopy for 
women with cervical dysplasia, with the option of 
expanding this approach to all HIV-positive women if local 
capacity allows.57 New York State (USA) recommends 
digital rectal examination for all HIV-positive women, and 
annual cytology for those with cervical HSIL.58 Thus, when 
recommendations for HIV-positive women exist, they tend 
to focus on women with cervical lesions and tend also to 
mirror those for HIV-positive MSM in the same setting.56–58 
The elevated anal cancer risk profile for HIV-positive 
women with cervical HSIL in the present work supports 
prioritisation over other HIV-positive women for secondary 
anal cancer prevention. However, in an era of shifting 
towards HPV-based cervical screening, the finding that 
HIV-positive women with cervical HPV16 infection (about 
10% of HIV-positive women in this pooled analysis) have 
an at least similar anal cancer risk profile suggests they 
deserve similar prioritisation.
Expanding secondary anal cancer prevention beyond 
HIV-positive women would pose substantial problems of 
upscaling and require appropriate weighting of benefit 
versus risk. Nevertheless, HIV-negative women with 
cervical HPV16 had an anal cancer risk profile similar to 
that of HIV-positive women (and HIV-positive MSM) and 
arguably deserve equivalent anal cancer prevention 
management. Indeed, in high-income settings, the 
population burden of female anal cancer is largely 
unaffected by HIV9,10 and so requires intervention in 
the HIV-negative population. As HPV-based cervical 
screening becomes more widespread, our findings 
advocate for further research into anal disease burden 
and prevention among HIV-negative cervical HPV16-
positive women. There should be a particular focus on 
older generations of women who have missed out on the 
opportunity of prevention through HPV vaccination and 
in whom cervical HPV16 infection is rarer and more 
likely to represent long-standing persistent infection. 
Although numbers were small, half of all cervical HPV16-
positive women aged older than 45 years harboured anal 
HPV16, and one quarter had HPV16-positive anal HSIL. 
Population-based anal cancer incidence begins to rise 
only in the fifth decade of life,10 10 years later than that for 
cervical cancer, so secondary prevention might also begin 
about 10 years later.
In summary, the prevalence of anal HPV16 infection, 
anal HSIL, or HPV16-positive HSIL can be used as 
surrogates to classify female subpopulations with 
different anal cancer risk. Such an approach is validated 
by identification of established high-risk groups—namely, 
women diagnosed with cervical precancer or cancer, or 
living with HIV. With respect to identifying the highest 
risk populations for targeted secondary prevention, 
HIV-negative women with cervical HPV16 infection, 
particularly those older than 45 years, had an anal cancer 
risk profile, based on these surrogate measures, that was 
similar to that of HIV-positive women.
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